STAT September 23, 2021
Billions of dollars have been spent in pursuit of a pharmaceutical treatment for Alzheimer’s and other forms of dementia. Their fail rate through the 21st century is stuck at 100%.
The dominant story promoted by Alzheimer’s advocacy organizations, pharmaceutical companies, and academic experts has been that, without a cure, aging societies will face a demographic tidal wave of dementia—a “silver tsunami” unleashing devastating socioeconomic consequences.
Yet dementia rates have actually fallen in the United States, Canada, the United Kingdom, France, Sweden and the Netherlands over the past decade even though biotechnology continues to come up short. A 2020 study compiling data from those six countries from 1988 to 2015 calculated that, while the overall number of people affected by dementia...
Today's Sponsors
Today's Sponsor